The trajectory of copyright's flagship drug presents a nuanced case for investors in the drug sector. While initially a tremendous success, producing huge profits, the patent expiration and the subsequent flood of cheaper alternatives have considerably affected revenue. This poses questions about the ongoing viability of similar therapeutic develop